Compare SOPH & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | OBIO |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 253.9M |
| IPO Year | 2021 | 2020 |
| Metric | SOPH | OBIO |
|---|---|---|
| Price | $7.50 | $4.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.50 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 422.9K | 176.4K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $3.10 | $2.20 |
| 52 Week High | $7.88 | $5.42 |
| Indicator | SOPH | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 62.64 |
| Support Level | $4.63 | $4.07 |
| Resistance Level | N/A | $4.76 |
| Average True Range (ATR) | 0.48 | 0.20 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 82.43 | 69.32 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.